Appili Net Income Per E B T from 2010 to 2026

APLI Stock  CAD 0.02  0.01  20.00%   
Appili Therapeutics Net Income Per E B T yearly trend continues to be very stable with very little volatility. Net Income Per E B T is likely to drop to 0.76. During the period from 2010 to 2026, Appili Therapeutics Net Income Per E B T quarterly data regression pattern had sample variance of  0.01 and median of  0.87. View All Fundamentals
 
Net Income Per E B T  
First Reported
2010-12-31
Previous Quarter
0.91
Current Value
0.76
Quarterly Volatility
0.10711181
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Appili Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Appili Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 4.6 M, Depreciation And Amortization of 11.3 K or Interest Expense of 4.2 M, as well as many indicators such as Price To Sales Ratio of 40.48, Dividend Yield of 0.0 or Days Sales Outstanding of 5.7 K. Appili financial statements analysis is a perfect complement when working with Appili Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Appili Therapeutics Technical models . Check out the analysis of Appili Therapeutics Correlation against competitors.
Evaluating Appili Therapeutics's Net Income Per E B T across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Appili Therapeutics's fundamental strength.

Latest Appili Therapeutics' Net Income Per E B T Growth Pattern

Below is the plot of the Net Income Per E B T of Appili Therapeutics over the last few years. It is Appili Therapeutics' Net Income Per E B T historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Appili Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income Per E B T10 Years Trend
Slightly volatile
   Net Income Per E B T   
       Timeline  

Appili Net Income Per E B T Regression Statistics

Arithmetic Mean0.87
Geometric Mean0.86
Coefficient Of Variation12.37
Mean Deviation0.1
Median0.87
Standard Deviation0.11
Sample Variance0.01
Range0.2587
R-Value0.68
Mean Square Error0.01
R-Squared0.46
Significance0
Slope0.01
Total Sum of Squares0.18

Appili Net Income Per E B T History

2025 0.91
2024 1.01
2023 1.02
2021 1.0
2019 0.96
2017 0.87

About Appili Therapeutics Financial Statements

Appili Therapeutics investors utilize fundamental indicators, such as Net Income Per E B T, to predict how Appili Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Income Per E B T 0.91  0.76 

Pair Trading with Appili Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Appili Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Appili Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Appili Stock

  0.39ETG Entree ResourcesPairCorr
  0.35LOVE Cannara BiotechPairCorr
  0.35BCE BCE IncPairCorr
  0.35RKR ROKMASTER Resources CorpPairCorr
  0.35NICU Magna MiningPairCorr
The ability to find closely correlated positions to Appili Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Appili Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Appili Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Appili Therapeutics to buy it.
The correlation of Appili Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Appili Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Appili Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Appili Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Appili Stock

Appili Therapeutics financial ratios help investors to determine whether Appili Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Appili with respect to the benefits of owning Appili Therapeutics security.